Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
暂无分享,去创建一个
G. Sauter | T. Schlomm | S. Steurer | T. Krech | C. Wittmer | R. Simon | W. Wilczak | S. Minner | M. Tsourlakis | H. Heinzer | M. Graefen | H. Huland | M. Kluth | C. Hube-Magg | E. Thomsen | C. Koop | N. Melling